The COVID-19 (coronavirus disease-19) pandemic affected more than 180 million people around the globe, causing more than five million deaths as of January 2022. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing; however, prophylactic drugs are highly demanded to ensure secure social contact. A number of drug molecules have been repurposed to fight against SARS-CoV-2, and some of them have been proven to be effective in preventing hospitalization or ICU admissions. Here, we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of SARS-CoV-2 and its variants, Delta and Omicron, into the Vero E6 cell lines and IFNAR-/-mouse models by attaching to the spike protein of SARS-CoV-2. Given the current mutation frequency of SARS-CoV-2, we believe that GRFT protein-based drugs will have a high impact in preventing the transmission of both the Wuhan strain as well as any other emerging variants, including Delta and Omicron variants, causing the high-speed spread of COVID-19.
CITATION STYLE
Ahan, R. E., Hanifehnezhad, A., Kehribar, E., Oguzoglu, T. C., Földes, K., Özçelik, C. E., … Şeker, U. Ö. Ş. (2022). A Highly Potent SARS-CoV-2 Blocking Lectin Protein. ACS Infectious Diseases, 8(7), 1253–1264. https://doi.org/10.1021/acsinfecdis.2c00006
Mendeley helps you to discover research relevant for your work.